Nevertheless, reflecting theoretical and clinical evidence, other guidelines highlight the use of GLP-1 RA treatment for people with type 2 diabetes and HF (Buse et al., 2020; Cosentino et al., 2019), for example, the ADA/EASD consensus statement have hitherto recommended the use of GLP-1 RA treatment in situations where HF (and/or chronic kidney disease [CKD]) is predominant and SGLT2 inhibitors not tolerated (Buse et al., 2020). This evidence concerns the gene SLC5A2 and chronic kidney disease.